Pre-made Monalizumab benchmark antibody ( Whole mAb, anti-KLRC1/NKG2A therapeutic antibody, Anti-CD159A/NKG2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Monalizumab biosimilar, Whole mAb, Anti-KLRC1/NKG2A Antibody: Anti-CD159A/NKG2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Monalizumab (formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-355-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Monalizumab biosimilar, Whole mAb, Anti-KLRC1/NKG2A Antibody: Anti-CD159A/NKG2 therapeutic antibody
INN Name	Monalizumab
Target	NKG2A
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Innate Pharma;MedImmune;NCIC Clinical Trials Group;Novo Nordisk
Conditions Approved	na
Conditions Active	Head and neck cancer;Non-small cell lung cancer;Cervical cancer;Chronic lymphocytic leukaemia;Endometrial cancer;Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Solid tumours;Haematological malignancies
Conditions Discontinued	Inflammation;Rheumatoid arthritis
Development Tech	na